Evidence map›Paper›PMID 31688149›Full record

ArticleJournal of addiction medicine

Validity of Self-reported Cannabis Use Among Pregnant Females in Northern California.

Kelly C Young-Wolff, Varada Sarovar, Lue-Yen Tucker, Nancy Goler, Amy Conway, Constance Weisner, Mary Anne Armstrong, Stacey Alexeeff

Open access · greenAbstract read
In one paragraph

Article in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Prenatal Cannabis Use and Depressive Symptoms.Obstetrics and gynecology · 2025
    Observational
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kelly C Young-WolffDivision of Research, Kaiser Permanente Northern California, Oakland, CA (KCY-W, VS, L-YT, CW, MAA, SA); Department of Psychiatry, Weill Institute for Neurosciences, University of California, San Francisco, CA (KCY-W, CW); Regional Offices, Kaiser Permanente Northern California, Oakland CA (NG); Early Start Program, Kaiser Permanente Northern California, Oakland CA (AC).
Varada Sarovar
Lue-Yen Tucker
Nancy Goler
Amy Conway
Constance Weisner
Mary Anne Armstrong
Stacey Alexeeff
Kaiser Permanente · USUniversity of California, San Francisco · US

Funding

Identifying Risk Factors for Prenatal Substance and Polysubstance UseK01DA043604 · NIDA · KAISER FOUNDATION RESEARCH INSTITUTE · PI YOUNG-WOLFF, KELLY CORINNE · 2017 to 2021
$907k
NIDA NIH HHS K01 DA043604
6 · The paper itself

Abstract

backgroundMost clinical and epidemiologic estimates of prenatal cannabis use are based on self-report, and the validity of self-reported cannabis use has not been examined in a large, representative population of pregnant women. We determined the validity of self-reported prenatal cannabis use and predictors of nondisclosure using data from Kaiser Permanente Northern California's (KPNC) healthcare system with universal prenatal cannabis screening during prenatal care.

methodsValidation study using data from 281,025 pregnancies in KPNC among females aged ≥11 years who completed a self-administered questionnaire on prenatal cannabis use and a cannabis urine toxicology test from 2009 to 2017. We calculated sensitivity, specificity, positive predictive value, and negative predictive value of self-reported prenatal cannabis use using urine toxicology testing as the criterion standard, and sensitivity of urine toxicology testing using self-reported use as the criterion standard. We compared sociodemographics of those who disclosed versus did not disclose prenatal cannabis use.

resultsUrine toxicology testing identified more instances of prenatal cannabis use than self-report (4.9% vs 2.5%). Sensitivity of self-reported use was low (33.9%). Sensitivity of the toxicology test was higher (65.8%), with greater detection of self-reported daily (83.9%) and weekly (77.4%) than monthly or less use (54.1%). Older women, those of Hispanic race/ethnicity, and those with lower median neighborhood incomes were most likely to be misclassified as not using cannabis by self-reported screening.

conclusionsGiven that many women choose not to disclose prenatal cannabis use, clinicians should educate all prenatal patients about the potential risks and advise them to quit cannabis use during pregnancy.

Indexed as

CannabisPregnant PeopleAgedCaliforniaFemaleHumansPregnancyPrenatal CareSelf Report

Identifiers

PMID31688149
PMCPMC7931632
OpenAlexW2988352271

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.